779 patents
Page 15 of 39
Utility
Time to Resolution of Axitinib-related Adverse Events
2 Jun 22
This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment.
Despoina Thomaidou
Filed: 30 Nov 21
Utility
Escherichia Coli Compositions and Methods Thereof
2 Jun 22
In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof.
Robert G.K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
Filed: 15 Feb 22
Utility
Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile
26 May 22
In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof.
Kathrin Ute Jansen, Annaliesa Sybil Anderson, Alexey Vyacheslavovitch Gribenko, Nicholas Randolph Everard Kitchin, Paul Liberator, Michael William Pride, Christopher Frederick Webber
Filed: 30 Mar 20
Utility
Toll-like receptor agonists
24 May 22
The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
Filed: 13 Jul 20
Utility
Tofacitinib Oral Sustained Release Dosage Forms
12 May 22
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof.
Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
Filed: 21 Jan 22
Utility
Nitrile-Containing Antiviral Compounds
12 May 22
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 17 Dec 21
Utility
Crystalline PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE Compound and Use Thereof
12 May 22
The present invention discloses a novel crystalline form of ((S)-2,2-difluorocyclopropyl)-((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone free base, pharmaceutical composition containing the same, preparations thereof and uses thereof.
Xiaojing YANG, Amanda Patrice Surajhie SAMUEL
Filed: 12 Feb 20
Utility
Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-OXO-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypryridin-2-YL)benzoic acid
10 May 22
The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.
Dilinie Fernando, Shawn Marie LaCasse, Kristin Elizabeth Price Wiglesworth
Filed: 14 Nov 18
Utility
Site-specific integration
10 May 22
The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g.
James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
Filed: 31 Oct 18
Utility
Methods for purifying bacterial polysaccharides
5 May 22
The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.
Ling Chu, Scott Andrew Cook, Nishith Merchant, Justin Keith Moran
Filed: 20 Feb 20
Utility
Method of treatment of Chronic Low Back Pain
5 May 22
The present invention relates to the treatment of chronic low back pain with an anti-nerve growth factor (NGF) antibody.
Christine Ruth WEST, Mark Thomas BROWN, Candace Roskoph BRAMSON
Filed: 14 Feb 20
Utility
Combination of a CDK Inhibitor and a Pim Inhibitor
28 Apr 22
This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.
Zhou Zhu, Yuan Liu
Filed: 31 Jan 20
Utility
Crystalline Form of a CDK Inhibitor
28 Apr 22
Douglas Carl Behenna, Martha Alicia Ornelas
Filed: 13 Jan 20
Utility
Manufacturing Process and Intermediates for a PYRROLO[2,3-D]PYRIMIDINE Compound and Use Thereof
28 Apr 22
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.
Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
Filed: 10 Jan 22
Utility
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
26 Apr 22
Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Michael Chen, Jotham Wadsworth Coe, Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Matthew Richard Reese, Colin Richard Rose, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Joseph Scott Warmus, Yuan Zhang
Filed: 6 Mar 18
Utility
Chimeric antigen receptors targeting B-cell maturation antigen
26 Apr 22
The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen).
Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Ariel Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
Filed: 15 Apr 19
Utility
Neisseria Meningitidis Compositions and Methods Thereof
21 Apr 22
In one aspect, the invention relates to use of a composition including a first polypeptide and a second polypeptide, wherein the composition elicits an immune response against Neisseria meningitis serogroup B strains expressing, for example, variants A02, A28, A42, A63, A76, B05, B07, B08, B13, B52 and B107.
Annaliesa Sybil Anderson, Paul Liberator, Thomas Richard Jones, Kathrin Ute Jansen, John Lance Perez, Shannon Lea Harris
Filed: 7 Feb 20
Utility
Substituted PYRAZOLO[1,5-A]PYRAZINE Compounds As Ret Kinase Inhibitors
21 Apr 22
Steven W. ANDREWS, James F. BLAKE, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, David A. MORENO, Li REN, Shane M. WALLS
Filed: 29 Oct 21
Utility
Antibodies to MAdCAM
21 Apr 22
The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM.
Karin Anderson
Filed: 4 Jun 21
Utility
CDCP1-TARGETED Therapies
21 Apr 22
The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.
Lewis C. CANTLEY, Stephen P. SOLTOFF, Brooke M. EMERLING, George POULOGIANNIS, Cindy M. HODAKOSKI, Hui LIU, Irina APOSTOLOU, Brian Gaither BATES, Kimberly Ann MARQUETTE, Eric M. BENNETT, Lidia MOSYAK, Lioudmila G. TCHISTIAKOVA, Edward Christian ROSFJORD, Isaac J. RONDON, Chao Bai HUANG
Filed: 7 Nov 19